ArticleArchives of dermatological research2024
The burden of skin diseases in China: global burden of Disease Study 2019.
Article in Archives of dermatological research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Therapeutic Potential of Extracellular Vesicles Derived from Sheep Placenta in the Treatment of Skin Disorders.ACS omega · 2026Article
- Effective treatment of scabetic nodules with thalidomide: a 5-year retrospective case series.BMC infectious diseases · 2026Article
- Burden of dermatology outpatient and inpatient services in China, 2011-2023.Frontiers in public health · 2026Article
- Burden of malignant melanoma among the elderly population in East Asia from 1990 to 2023 and machine learning projection to 2040.PloS one · 2026Article
- International Expert Consensus on Defining Skin of Color and Delivering Equitable Dermatologic Care.International journal of dermatology · 2026Article
- Epidemiological trends and future burden of skin and subcutaneous diseases in China: insights from the global burden of disease study 2021.Frontiers in medicine · 2026Article
- Changes in Clinical Trials of Dermatological Drugs in Mainland China Between 2016 and 2022: A Narrative Review.Therapeutic innovation & regulatory science · 2025Review
- Analysis and comparison of the trends in burden of malignant cutaneous melanoma in East Asian countries and regions and worldwide from 1991 to 2021.Frontiers in public health · 2025Article
- Extracellular Vesicles in Skin: Biological Function and Therapeutic Potential.International journal of nanomedicine · 2025Review
- An explainable hybrid deep learning framework for precise skin lesion segmentation and multi-class classification.Frontiers in medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Skin diseases continue to affect human health and cause a significant disease burden on the healthcare system.We aimed to report the changing trends in the burden of skin disease in China from 1990 to 2019, Which has an important role in developing targeted prevention strategies. We applied Global Burden of Disease, Injuries, and Risk Factors Study (GBD) 2019 analytical tools to calculate the age-standardized Prevalence and Incidence in 2019, number of years lived with disability (YLDs) and age-standardized YLDs from 1990 to 2019 of skin and subcutaneous diseases, notifiable infectious skin diseases and skin tumors in China. Among the skin and subcutaneous diseases in China in 2019, dermatitis contributed to the greatest YLD (2.17 million, 95% uncertainty interval[UI]: 1.28-3.36). Age-standardized YLD rates for leprosy decreased from 0.09 (95%UI: 0.06-0.13) in 1990 to 0.04 (95%UI: 0.03-0.06) in 2019; the proportional decrease was 55.56% over 30 years. Age-standardized YLDs for HIV and sexually transmitted infections increased by 26% during the same time period. Age-standardized YLDs for non-melanoma skin cancer increased at a much higher rate than melanoma between 1990 and 2019. Dermatitis and scabies continue to have an important role in the burden of skin and subcutaneous disease burden in China. The burden of non-melanoma cell cancer has increased most significantly over the past three decades.
Indexed as
Identifiers
38796625What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.